in vitro model News
-
TCT 2017 Poster Shows Impact of Strut Thickness on Thrombogenicity in BRS
ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of thrombus. Shengjui, from Nicolas ...
-
Superiority vs gold standard demonstrated by in-vitro model
Biofilm creation - among others - is one of the most important factors linked to infections and almost the only one that can be measured through simulation. T-Control demonstrated superiority vs gold standard, i.e. significant differences were observed between the biofilm quantity generated on the product´s surface. This result reinforces the hypothesis that T-Control, with it´s ...
-
Stem Pharm Senior Scientist, Joshua Zimmermann, Gives a Talk on Biomaterials for 3D Applications at SELECT BIO’s “Introduction to Implementing 3D Culture Models” Webinar, Sponsored by Promega
Through control of properties such as substrate mechanical stiffness and adhesion ligand presentation, materials can be designed that enable more physiologically relevant extracellular environments and better direct cellular behaviors within 3D models. At Stem Pharm, we are applying these principles to design PEG-based hydrogels for the development of in vitro neural models. ...
-
Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease Therapeutics
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program. The award will enable development of a novel ...
-
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range
Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS) The companies share a common goal of developing and supplying advanced cell models that better reflect an in vivo environment to improve drug discovery accuracy ...
-
VIVAX BIO on a mission for COVID-19 drug discovery
Following its aspiring mission “Creating future opportunities” the biotechnological research laboratory “3D Bioprinting Solutions” and VIVAX BIO take an active part in pharmacological studies of various antiviral drugs. During the most difficult challenge in recent healthcare history cell biologists from the laboratory's research team began working with leading virologists ...
-
Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz Supercharged Autologous Immunotherapy Platform
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company's ImmCelz® ...
-
Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that ...
-
Agilent Technologies Thought Leader Award Supports Dr. Paul Watkins, Hamner-UNC Institute for Drug Safety Sciences
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Paul B. Watkins, international drug safety expert and director of the Hamner-University of North Carolina Institute for Drug Safety Sciences, has received an Agilent Thought Leader Award in recognition of his ongoing work developing integrated methods to predict drug-induced liver injury (DILI). This award continues Agilent's support ...
-
Gain Therapeutics Presents Preclinical Data On Its Structurally Targeted Allosteric Regulators In GBA1 Gaucher Disease At The WORLDSymposium 2022
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functions BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric ...
-
Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism, demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). The company has initiated the HERO (HElp ...
-
Dieter Lutticken Award 2009 for development of in vitro bovine respiratory tract organ culture model
The Dieter Lütticken Award 2009, a prestigious international annual award dedicated to alternatives in animal testing for veterinary medicines, goes to Dr. A.W. (Dan) Tucker, senior lecturer in veterinary public health at the University of Cambridge (United Kingdom). He will receive the € 20,000 award, which is sponsored by Intervet/Schering-Plough Animal Health, for the development of ...
-
MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma
MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model. MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a Netherlands-based company specializing ...
-
Full-Scale PROTAC In Vivo Evaluation Services to Facilitate PROTAC Drug R&D
In the process of drug development, the evaluation of drug effectiveness is one of the keys to determining whether prodrugs can sufficiently reach the market stage. BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC ...
By BOC Sciences
-
Eligo Presents Preclinical Data Demonstrating for the First Time that Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome), at the 14th Annual CRISPR 2021 meeting held June 1-10, 2021. The data presented further supports ...
-
BIOtechNOW featured IVS’s participating BIO Innovation Zone
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) to advance a synthetic T ...
-
New Culture Medium Supports Expansion of Natural Killer Cells for Cell and Gene Therapies
Thermo Fisher Scientific today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. This is the first medium from Thermo Fisher specifically designed to support expansion of NK cells for cell therapy ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you